Classification of cancer chemotherapeutic drugs according to their ability to potentiate contact sensitivity to dinitrofluorobenzene.
The anticancer chemotherapeutic drugs cyclophosphamide (CY), melphalan (L-phenylalanine mustard; L-PAM), 5-fluorouracil (5-FU), methotrexate (MTX), and daunorubicin (DAU) were tested for ability to potentiate contact sensitization (CS) to dinitrofluorobenzene (DNFB) in mice and to inhibit induction of unresponsiveness to such sensitization by preceding exposure to dinitrobenzenesulfonate (DNBS). Administration of CY and L-PAM but not of 5-FU, MTX, and DAU, after DNBS treatment (and before DNFB sensitization) reduced the degree of unresponsiveness effected by DNBS. It is suggested that the test system of CS might be utilized for screening the ability of cancer chemotherapeutic agents to act as nonspecific immuno-modulators.
D000818:Animals; D000970:Antineoplastic Agents / Q000145:classification* / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D003877:Dermatitis, Contact / Q000209:etiology*; D004139:Dinitrofluorobenzene / Q000031:analogs & derivatives / Q000494:pharmacology*; D004357:Drug Synergism; D008558:Melphalan / Q000494:pharmacology; D008727:Methotrexate / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D009578:Nitrobenzenes / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000187:drug effects
D000970:Antineoplastic Agents; D009578:Nitrobenzenes; C045305:2,4-dinitrofluorobenzene sulfonic acid; D003520:Cyclophosphamide; D004139:Dinitrofluorobenzene; D008558:Melphalan; D008727:Methotrexate; D003630:Daunorubicin